$8.12▴ 1.63%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$2.20cash per $1 profit
Strong
It turns every reported profit-dollar into real cash, and then some.
Valuation
98th pctvs its own history
Rich
Its valuation sits in the richer end of its own recent range.
Revenue growth
-2.6%year over year
Weak
Revenue is contracting year over year.
Leverage
Lowdebt to assets
Strong
Very low debt relative to its asset base.
More coming: dilution / share-count creep.
Fair value
Undervalued
Trading about 42% below our fair-value range
Balance-sheet caution
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Puma Biotechnology Inc turns 220¢ of every reported profit-dollar into real cash. Revenue is contracting year over year. Its valuation sits in the richer end of its own recent range. Very low debt relative to its asset base.
Key numbers
Valuation
EPS (TTM)$0.48
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin10.7%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$227.18M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.